Reported 1 day ago
Viking Therapeutics (NASDAQ: VKTX) continues to impress investors with strong data from its cardiometabolic disease programs, particularly VK2809 which shows promising results in treating metabolic dysfunction-associated steatohepatitis (MASH). Recent phase 2b clinical trial outcomes indicated significant improvements in patients' liver health, positioning VK2809 for a phase 3 trial and highlighting Viking's potential for growth within a lucrative market projected to exceed $16 billion by 2030. Coupled with the successful VK2735 for obesity and strong financial backing with $930 million in cash, Viking Therapeutics stands on the brink of commercial success with two promising drugs poised for market entry.
Source: YAHOO